Perseus Proteomics Inc. (TYO:4882)
141.00
-4.00 (-2.76%)
Aug 19, 2026, 3:30 PM JST
Perseus Proteomics Revenue
Perseus Proteomics had revenue of 35.18M JPY in the quarter ending June 30, 2026, with 49.90% growth. This brings the company's revenue in the last twelve months to 147.22M, up 19.70% year-over-year. In the fiscal year ending March 31, 2026, Perseus Proteomics had annual revenue of 135.00M with 12.50% growth.
Revenue (ttm)
147.22M
Revenue Growth
+19.70%
P/S Ratio
18.15
Revenue / Employee
n/a
Employees
35
Market Cap
2.67B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 135.00M | 15.00M | 12.50% |
| Mar 31, 2025 | 120.00M | 20.00M | 20.00% |
| Mar 31, 2024 | 100.00M | 6.00M | 6.38% |
| Mar 31, 2023 | 94.00M | 23.00M | 32.39% |
| Mar 31, 2022 | 71.00M | 4.00M | 5.97% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.62T |
| Astellas Pharma | 2.27T |
| Daiichi Sankyo Company | 2.22T |
| Chugai Pharmaceutical | 1.34T |
| Kyowa Kirin | 529.80B |
| Ono Pharmaceutical | 504.41B |
| Santen Pharmaceutical | 291.84B |
| JCR Pharmaceuticals | 41.45B |